LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 22

Search options

  1. Article ; Online: MAIT cells altered phenotype and cytotoxicity in lupus patients are linked to renal disease severity and outcome.

    Litvinova, Elena / Bounaix, Carine / Hanouna, Guillaume / Da Silva, Jennifer / Noailles, Laura / Beaudoin, Lucie / Padden, Michael / Bellamri, Nessrine / Lehuen, Agnès / Daugas, Eric / Monteiro, Renato C / Flament, Héloïse

    Frontiers in immunology

    2023  Volume 14, Page(s) 1205405

    Abstract: Introduction: Systemic lupus erythematosus (SLE) is an autoimmune disease in which circulating immune complexes can cause different types of glomerulonephritis, according to immune deposits and to the type of glomerular cell injury. Proliferative ... ...

    Abstract Introduction: Systemic lupus erythematosus (SLE) is an autoimmune disease in which circulating immune complexes can cause different types of glomerulonephritis, according to immune deposits and to the type of glomerular cell injury. Proliferative lesions represent the most severe form of lupus nephritis (LN) and often lead to kidney failure and death. Mucosal-associated invariant T (MAIT) cells are a subset of innate-like T cells that recognize microbial-derived ligands from the riboflavin synthesis pathway. Although abundant in peripheral blood, MAIT cells are enriched in mucosal and inflamed tissues. While previous studies have reported concordant results concerning lower MAIT cell frequencies in the blood of SLE patients, no information is known about MAIT cell function and LN severity and outcome.
    Methods: In the current study, we analyzed the baseline phenotype and function of peripheral blood MAIT cells by flow cytometry in 26 patients with LN and in a control group of 16 healthy individuals.
    Results: We observe that MAIT cell frequencies are markedly reduced in blood of LN patients. MAIT cells from patients have an altered phenotype in terms of migration, proliferation and differentiation markers, notably in most severe forms of LN. Frequencies of PMA/ionomycin stimulated MAIT cells secreting effector molecules, such as proinflammatory IL-17 and cytotoxic protein granzyme B, are higher in LN patients. Patients undergoing a complete renal remission after immunosuppressive therapy had higher MAIT cell frequency, lower expression of proliferation marker Ki-67 and granzyme B (GzB) at inclusion. Remarkably, GzB production defines a predictive model for complete remission.
    Discussion: We report here that blood MAIT cells display proinflammatory and cytotoxic function in severe lupus nephritis which may play a pathogenesis role, but without association with systemic lupus activity. Finally, low cytotoxic profile of MAIT cells may represent a promising prognostic factor of lupus nephritis remission one year after induction therapy.
    MeSH term(s) Humans ; Lupus Nephritis ; Mucosal-Associated Invariant T Cells ; Granzymes ; Lupus Erythematosus, Systemic ; Phenotype ; Patient Acuity
    Chemical Substances Granzymes (EC 3.4.21.-)
    Language English
    Publishing date 2023-10-10
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2023.1205405
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: New therapeutic perspectives for IgA nephropathy in children.

    Cambier, Alexandra / Gleeson, Patrick J / Flament, Héloise / Le Stang, Marie-Bénédicte / Monteiro, Renato C

    Pediatric nephrology (Berlin, Germany)

    2020  Volume 36, Issue 3, Page(s) 497–506

    Abstract: Childhood IgA nephropathy (cIgAN) differs from the adult by having an abrupt clinical onset, often presenting as an acute attack that can progress to a chronic phase. No treatment guidelines have been established for the treatment of cIgAN. Given the ... ...

    Abstract Childhood IgA nephropathy (cIgAN) differs from the adult by having an abrupt clinical onset, often presenting as an acute attack that can progress to a chronic phase. No treatment guidelines have been established for the treatment of cIgAN. Given the severity of acute attack in children, and the number of life-years at stake, pediatricians prescribe immunosuppression in addition to renin-angiotensin system blockade. Non-specific immunosuppressors, such as corticosteroids, have systemic toxic effects, and given recent therapeutic advances in adult glomerulonephritis, new tailored strategies should be expected for children. The mucosal immune system has been highlighted as a key player in IgAN pathogenesis, and several biomarkers have been identified with a direct role in pathogenesis. In this review, we discuss current studies of conventional and novel therapeutic approaches for cIgAN.
    MeSH term(s) Child ; Glomerulonephritis, IGA/diagnosis ; Glomerulonephritis, IGA/drug therapy ; Humans ; Immunoglobulin A ; Immunosuppression Therapy ; Renin-Angiotensin System
    Chemical Substances Immunoglobulin A
    Language English
    Publishing date 2020-02-10
    Publishing country Germany
    Document type Journal Article ; Review
    ZDB-ID 631932-4
    ISSN 1432-198X ; 0931-041X
    ISSN (online) 1432-198X
    ISSN 0931-041X
    DOI 10.1007/s00467-020-04475-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: The (Fab)ulous Destiny of Idarucizumab: Highlighting Its Interference with Urine Protein Immunofixation.

    Gendron, Nicolas / Flament, Héloïse / Litvinova, Elena / Ortuno, Sofia / Ajzenberg, Nadine / Faille, Dorothée

    TH open : companion journal to thrombosis and haemostasis

    2019  Volume 3, Issue 3, Page(s) e306–e308

    Abstract: Idarucizumab is a humanized antigen binding fragment (Fab) of a recombinant anti-dabigatran monoclonal antibody (IgG1-kappa) that allows rapid and sustained reversal of dabigatran-induced anticoagulation in case of bleeding or urgent surgery. Herein, we ... ...

    Abstract Idarucizumab is a humanized antigen binding fragment (Fab) of a recombinant anti-dabigatran monoclonal antibody (IgG1-kappa) that allows rapid and sustained reversal of dabigatran-induced anticoagulation in case of bleeding or urgent surgery. Herein, we report a very unusual case of dabigatran reversal by idarucizumab in a 79-year-old woman with acute kidney failure admitted to a hospital in a context of hemoptysis. Three repeated injections were necessary because of massive dabigatran overdose and high rebounds of dabigatran plasma concentration. Idarucizumab was found on urine immunofixation up to 6 days after the last injection where it reacted with anti-kappa light chain antibody, but not with anti-gamma heavy chain antibody. Physicians should be aware of the increased half-life of idarucizumab in this context of acute kidney impairment and of its interference with urine immunofixation because it could lead to false-positive results and misdiagnosis of a paraprotein.
    Language English
    Publishing date 2019-09-16
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 2901738-5
    ISSN 2512-9465 ; 2567-3459
    ISSN (online) 2512-9465
    ISSN 2567-3459
    DOI 10.1055/s-0039-1697642
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses.

    Gounant, Valérie / Ferré, Valentine Marie / Soussi, Ghassen / Charpentier, Charlotte / Flament, Héloïse / Fidouh, Nadhira / Collin, Gilles / Namour, Céline / Assoun, Sandra / Bizot, Alexandra / Brouk, Zohra / Vicaut, Eric / Teixeira, Luis / Descamps, Diane / Zalcman, Gérard

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

    2021  Volume 17, Issue 2, Page(s) 239–251

    Abstract: Introduction: Coronavirus disease 2019 resulted in a 30% mortality rate in patients with thoracic cancer. Given that patients with cancer were excluded from serum antisevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine registration ... ...

    Abstract Introduction: Coronavirus disease 2019 resulted in a 30% mortality rate in patients with thoracic cancer. Given that patients with cancer were excluded from serum antisevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine registration trials, it is still unknown whether they would develop a protective antispike antibody response after vaccination. This prospective vaccine monitoring study primarily aimed to assess humoral responses to the SARS-CoV-2 vaccine in patients with thoracic cancer.
    Methods: SARS-CoV-2-spike antibodies were measured using the Abbot Architect SARS-CoV-2 immunoglobulin G immunoassay before the first injection of BNT162b2 mRNA vaccine, at week 4, and 2 to 16 weeks after the second vaccine dose administration. The factors associated with antibody response were analyzed.
    Results: Overall, 306 patients, with a median age of 67.0 years (interquartile range: 58-74), were vaccinated. Of these, 283 patients received two vaccine doses at 28-day intervals. After a 6.7-month median follow-up, eight patients (2.6%) contracted proven symptomatic SARS-CoV-2 infection, with rapid favorable evolution. Of the 269 serologic results available beyond day 14 after the second vaccine dose administration, 17 patients (6.3%) were still negative (<50 arbitrary units/mL, whereas 34 (11%) were less than 300 arbitrary units/mL (12.5th percentile). In multivariate analysis, only age (p < 0.01) and long-term corticosteroid treatment (p = 0.01) were significantly associated with a lack of immunization. A total of 30 patients received a third vaccine dose, with only three patients showing persistently negative serology thereafter, whereas the others exhibited clear seroconversion.
    Conclusions: SARS-CoV2 vaccines were found to be efficient in patients with thoracic cancer, most of them being immunized after two doses. A third shot given to 1% of patients with persistent low antibody titers resulted in an 88% immunization rate.
    MeSH term(s) Aged ; BNT162 Vaccine ; COVID-19 ; COVID-19 Vaccines ; Humans ; Lung Neoplasms ; Prospective Studies ; RNA, Viral ; SARS-CoV-2 ; Vaccines, Synthetic ; mRNA Vaccines
    Chemical Substances COVID-19 Vaccines ; RNA, Viral ; Vaccines, Synthetic ; mRNA Vaccines ; BNT162 Vaccine (N38TVC63NU)
    Language English
    Publishing date 2021-11-16
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2432037-7
    ISSN 1556-1380 ; 1556-0864
    ISSN (online) 1556-1380
    ISSN 1556-0864
    DOI 10.1016/j.jtho.2021.10.015
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: The (Fab)ulous Destiny of Idarucizumab: Highlighting Its Interference with Urine Protein Immunofixation

    Gendron, Nicolas / Flament, Héloïse / Litvinova, Elena / Ortuno, Sofia / Ajzenberg, Nadine / Faille, Dorothée

    TH Open

    2019  Volume 03, Issue 03, Page(s) e306–e308

    Abstract: Idarucizumab is a humanized antigen binding fragment (Fab) of a recombinant anti-dabigatran monoclonal antibody (IgG1-kappa) that allows rapid and sustained reversal of dabigatran-induced anticoagulation in case of bleeding or urgent surgery. Herein, we ... ...

    Abstract Idarucizumab is a humanized antigen binding fragment (Fab) of a recombinant anti-dabigatran monoclonal antibody (IgG1-kappa) that allows rapid and sustained reversal of dabigatran-induced anticoagulation in case of bleeding or urgent surgery. Herein, we report a very unusual case of dabigatran reversal by idarucizumab in a 79-year-old woman with acute kidney failure admitted to a hospital in a context of hemoptysis. Three repeated injections were necessary because of massive dabigatran overdose and high rebounds of dabigatran plasma concentration. Idarucizumab was found on urine immunofixation up to 6 days after the last injection where it reacted with anti-kappa light chain antibody, but not with anti-gamma heavy chain antibody. Physicians should be aware of the increased half-life of idarucizumab in this context of acute kidney impairment and of its interference with urine immunofixation because it could lead to false-positive results and misdiagnosis of a paraprotein.
    Keywords idarucizumab ; dabigatran ; reversal ; immunofixation ; paraprotein
    Language English
    Publishing date 2019-07-01
    Publisher Georg Thieme Verlag KG
    Publishing place Stuttgart ; New York
    Document type Article
    ZDB-ID 2901738-5
    ISSN 2512-9465 ; 2567-3459
    ISSN (online) 2512-9465
    ISSN 2567-3459
    DOI 10.1055/s-0039-1697642
    Database Thieme publisher's database

    More links

    Kategorien

  6. Article ; Online: Correction: Modeling the Specific CD4

    Flament, Héloïse / Ramirez, Ruby Alonso / Prémel, Virginie / Joncker, Nathalie T / Jacquet, Alexandra / Scholl, Suzy / Lantz, Olivier

    Journal of immunology (Baltimore, Md. : 1950)

    2017  Volume 199, Issue 4, Page(s) 1526

    Language English
    Publishing date 2017-08-15
    Publishing country United States
    Document type Journal Article ; Published Erratum
    ZDB-ID 3056-9
    ISSN 1550-6606 ; 0022-1767 ; 1048-3233 ; 1047-7381
    ISSN (online) 1550-6606
    ISSN 0022-1767 ; 1048-3233 ; 1047-7381
    DOI 10.4049/jimmunol.1700890
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Protective role of mouse IgG1 in cryoglobulinaemia; insights from an animal model and relevance to human pathology.

    Chemouny, Jonathan Maurice / Hurtado-Nedelec, Margarita / Flament, Héloïse / Ben Mkaddem, Sanae / Daugas, Eric / Vrtovsnik, François / Berthelot, Laureline / Monteiro, Renato C

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

    2016  Volume 31, Issue 8, Page(s) 1235–1242

    Abstract: Strait et al. described a novel mouse model of cryoglobulinaemia by challenging mice deficient in the immunoglobulin (Ig)G1 subclass (γ1(-) mice) with goat anti-mouse IgD [5]. The phenotype of wild-type mice was not remarkable, whereas γ1(-) mice ... ...

    Abstract Strait et al. described a novel mouse model of cryoglobulinaemia by challenging mice deficient in the immunoglobulin (Ig)G1 subclass (γ1(-) mice) with goat anti-mouse IgD [5]. The phenotype of wild-type mice was not remarkable, whereas γ1(-) mice developed IgG3 anti-goat IgG cryoglobulins as well as severe and lethal glomerulonephritis. Renal phenotype could not be rescued in γ1(-) mice by the deletion of C3, fragment crystalline γ receptor (FcγR) or J chain. On the other hand, early injection of IgG1, IgG2a or IgG2b inhibited the pathogenic effects of IgG3 in an antigen-dependent manner even in the absence of the FcγRIIb, an anti-inflammatory receptor. The authors concluded that the pathogenic role of IgG3 and the protective characteristic of IgG1 in this model were not explained by their abilities to bind to FcRs or effector molecules but are rather due to structural discrepancies enhancing the precipitation properties/solubility of IgG3/IgG1-containing immune complexes. The present article aims to discuss the current knowledge on IgG biology and the properties of IgGs explaining their differential propensity to acquire cryoglobulin activity.
    MeSH term(s) Animals ; Cryoglobulinemia/immunology ; Cryoglobulinemia/pathology ; Cryoglobulinemia/prevention & control ; Disease Models, Animal ; Humans ; Immunoglobulin G/therapeutic use ; Mice
    Chemical Substances Immunoglobulin G
    Language English
    Publishing date 2016-08
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 90594-x
    ISSN 1460-2385 ; 0931-0509
    ISSN (online) 1460-2385
    ISSN 0931-0509
    DOI 10.1093/ndt/gfv335
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Efficacy of SARS-CoV-2 vaccine in thoracic cancer patients: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses

    GOUNANT, Valerie / FERRE, Valentine Marie / SOUSSI, Ghassen / charpentier, Charlotte / FLAMENT, Heloise / FIDOUH, Nadhira / COLLIN, Gilles / NAMOUR, Celine / ASSOUN, Sandra / BIZOT, Alexandra / BROUK, Zohra / VICAUT, Eric / TEXEIRA, Luis / DESCAMPS, Diane / ZALCMAN, Gerard

    medRxiv

    Abstract: Hypothesis Coronavirus disease 2019 (COVID-19) resulted in a 30% mortality rate in thoracic cancer patients. Given that cancer patients were excluded from serum anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine registration trials, ...

    Abstract Hypothesis Coronavirus disease 2019 (COVID-19) resulted in a 30% mortality rate in thoracic cancer patients. Given that cancer patients were excluded from serum anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine registration trials, it is still unknown whether they would develop a protective anti-spike antibody response following vaccination. This prospective vaccine monitoring study primarily aimed to assess humoral responses to SARS-CoV2 vaccine in thoracic cancer patients. Methods SARS-CoV2-spike antibodies were measured using Abbot ARCHITECT SARS-CoV-2 IgG immunoassay, prior to first injection of BNT162b2 mRNA vaccine, as well as at Week 4, and two-to-sixteen weeks after second vaccine dose. The factors associated with antibody response were analyzed. Results Overall, 306 patients, with a median age of 67.0 years (IQR=58-74), were vaccinated. Of these, 283 patients received two vaccine doses at 28-day intervals. After 4.7-month median follow-up, seven patients (2.3%) contracted proven symptomatic SARS-CoV-2 infection, with rapid favorable evolution. Of 269 serological results available beyond Day 14 post-second vaccine dose, 17 (6.3%) were still negative (<50 AU/mL) (arbitrary units/mL), while 34 (11%) were <300 AU/mL (12.5th percentile). In multivariate analysis, only age and chronic corticosteroid treatment were significantly associated with a lack of immunization. Thirty patients received a third vaccine dose, with only three patients showing persistent negative serology thereafter, whereas the others demonstrated clear seroconversion. Conclusion SARS-CoV2 vaccines were shown to be efficient in thoracic cancer patients, most of them being immunized after two doses. A third shot given to 11% of patients with persistent low antibody titers resulted in a 88% immunization rate.
    Keywords covid19
    Language English
    Publishing date 2021-08-13
    Publisher Cold Spring Harbor Laboratory Press
    Document type Article ; Online
    DOI 10.1101/2021.08.12.21261806
    Database COVID19

    Kategorien

  9. Article ; Online: Induction of anergic or regulatory tumor-specific CD4

    Alonso, Ruby / Flament, Héloïse / Lemoine, Sébastien / Sedlik, Christine / Bottasso, Emanuel / Péguillet, Isabel / Prémel, Virginie / Denizeau, Jordan / Salou, Marion / Darbois, Aurélie / Núñez, Nicolás Gonzalo / Salomon, Benoit / Gross, David / Piaggio, Eliane / Lantz, Olivier

    Nature communications

    2018  Volume 9, Issue 1, Page(s) 2113

    Abstract: ... ...

    Abstract CD4
    MeSH term(s) Adenocarcinoma of Lung/immunology ; Animals ; Antigens, Neoplasm/immunology ; Cell Differentiation/immunology ; Cell Line ; Clonal Anergy/immunology ; Disease Models, Animal ; Female ; HEK293 Cells ; Humans ; Immune Tolerance/immunology ; Lymph Nodes/cytology ; Lymph Nodes/immunology ; Lymphocyte Activation/immunology ; Mice ; Mice, Knockout ; T-Lymphocytes, Regulatory/immunology ; Tumor Escape/immunology
    Chemical Substances Antigens, Neoplasm
    Language English
    Publishing date 2018-05-29
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2553671-0
    ISSN 2041-1723 ; 2041-1723
    ISSN (online) 2041-1723
    ISSN 2041-1723
    DOI 10.1038/s41467-018-04524-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Induction of anergic or regulatory tumor-specific CD4+ T cells in the tumor-draining lymph node

    Ruby Alonso / Héloïse Flament / Sébastien Lemoine / Christine Sedlik / Emanuel Bottasso / Isabel Péguillet / Virginie Prémel / Jordan Denizeau / Marion Salou / Aurélie Darbois / Nicolás Gonzalo Núñez / Benoit Salomon / David Gross / Eliane Piaggio / Olivier Lantz

    Nature Communications, Vol 9, Iss 1, Pp 1-

    2018  Volume 17

    Abstract: Tumor neoantigens can be drained to the lymph nodes, but the nature and the significance of the induced immune responses are still unclear. Here the authors use a mouse genetic tumor model to show that tumor-specific CD4 T cells can become anergic or ... ...

    Abstract Tumor neoantigens can be drained to the lymph nodes, but the nature and the significance of the induced immune responses are still unclear. Here the authors use a mouse genetic tumor model to show that tumor-specific CD4 T cells can become anergic or suppressive in the draining lymph node to modulate tumor immunity.
    Keywords Science ; Q
    Language English
    Publishing date 2018-05-01T00:00:00Z
    Publisher Nature Publishing Group
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top